Status:
COMPLETED
Collection of Blood Samples From Patients With Relapsing MS Who Developed ITP After Receiving Lemtrada
Lead Sponsor:
Genzyme, a Sanofi Company
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Primary Objective: To collect blood samples in a new cohort of Relapsing Forms of Multiple Sclerosis (RMS) participants who had developed immune thrombocytopenic purpura (ITP) after LEMTRADA treatmen...
Detailed Description
One to 70 days, as screening and inclusion visit(s) were performed the same day or on separate days with a maximum timeframe of 30 days apart. One visit was required for blood draw. However, if a seco...
Eligibility Criteria
Inclusion
- Inclusion criteria :
- Male and female adult participants who had been treated with LEMTRADA, with development of ITP subsequent to treatment. Participants does not need to be currently on LEMTRADA treatment.
- Participants who had signed the study ICF.
- Exclusion criteria:
- \- Not applicable
- The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Exclusion
Key Trial Info
Start Date :
February 8 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 11 2019
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT03784898
Start Date
February 8 2019
End Date
December 11 2019
Last Update
March 28 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Investigational Site Number 8400001
Los Angeles, California, United States, 90094